Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury

• US 20070259032A1
• Filed: 05/01/2007
• Published: 11/08/2007
• Est. Priority Date: 05/01/2006
• Status: Active Grant

• Current Assignee: Johns Hopkins University, Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Bright, Corinne, Bright, Rachel, Leong, Kam, Churchill, Eric, Rosen, Daria
• Granted Patent: US 8,697,120 B2
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/78 of acrylic acid or derivatives thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/5138 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue.

Claims

1. A method for protecting tissue from ischemic injury, comprising administering a composition comprising a nanodevice.

2. The method of claim 1, wherein said nanodevice is selected from the group consisting of nanoparticles, nanorods, nanospheres, liposomes, micelles, and nanobubbles.

3. The method of claim 1, wherein said nanodevice is a polymeric nanodevice.

4. The method of claim 3, wherein the polymer is a biodegradable or nonbiodegradable polymer.

5. The method of claim 3, wherein the polymer is poly(methylidene malonate 2.1.2) (PMM 2.1.2).

6. The method of claim 1, wherein said administering comprises administering a plurality of nanodevices.

7. The method of claim 1, wherein said administering comprises administering to a subject prior to surgery.

8. The method of claim 1, wherein said tissue is heart tissue at risk of myocardial infarction.

9. The method of claim 1, wherein said administering comprises administering to a subject at risk of ischemic damage due to myocardial infarction or stroke.

10. The method of claim 1, wherein said administering comprising administering nanodevices further comprising a therapeutic agent.

11. A method for reducing ischemic reperfusion injury to a tissue, comprising delivering intravascularly to the tissue a composition comprised of nanodevices.

12. The method of claim 11, wherein said administering comprises administering during organ or tissue harvest.

13. The method of claim 11, wherein said administering comprises administering during organ or tissue transplantation.

14. The method of claim 11, wherein said administering comprises administering during surgery.

15. The method of claim 11, wherein said administering comprises administering polymeric nanodevices.

16. The method of claim 11, wherein said administering comprises administering lipidic nanodevices.

17. The method of claim 11, wherein said administering comprises administering nanodevices further comprising a therapeutic agent.

18. A method for conferring protection to a tissue at risk of ischemic injury, comprising administering intravascularly to the tissue a composition comprised of polymer or lipidic nanodevices.

19. The method of claim 18, wherein said administering comprising administering prior to a scheduled ischemic event.

20. The method of claim 19, wherein said scheduled ischemic event is surgery.

21. The method of claim 20, wherein said administering is at least about 12 hours prior to surgery.

22. The method of claim 18, wherein said administering comprising administering chronically prior to an unscheduled ischemic event.

23. The method of claim 22, wherein said administering is at least about monthly.

24. The method of claim 18, wherein said administering comprising administering lipidic nanodevices in the form of liposomes or micelles.

25. The method of claim 18, wherein said administering comprising administering nanodevices further comprising a therapeutic agent.